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Selective Ablation of Glucocorticoid Receptor in
Mouse Keratinocytes Increases Susceptibility to Skin
Tumorigenesis
Vı´ctor Latorre1, Lisa M. Sevilla1, Ana Sanchis1 and Paloma Pe´rez1
We recently demonstrated that mice lacking the epidermal glucocorticoid (GC) receptor (GR) (GR epidermal
knockout (GREKO) mice) have developmental defects and sensitivity to epidermal challenge in adulthood. We
examined the susceptibility of GREKO mice to skin chemical carcinogenesis. GREKO mice treated with a low dose
of 12-dimethylbenz(a) anthracene (DMBA) followed by phorbol 12-myristate 13-acetate (PMA) promotion
exhibited earlier papilloma formation with higher incidence and multiplicity relative to control littermates
(CO). Augmented proliferation and inflammation and defective differentiation of GREKO keratinocytes con-
tributed to the phenotype, likely through increased AKT and STAT3 (signal transducer and activator of
transcription 3) activities. GREKO tumors exhibited signs of early malignization, including delocalized expression
of laminin A, dermal invasion of keratin 5 (K5)–positive cells, K13 expression, and focal loss of E-cadherin.
Cultured GREKO keratinocytes were spindle like, with loss of E-cadherin and upregulation of smooth muscle actin
(SMA) and Snail, suggesting partial epithelial–mesenchymal transition. A high DMBA dose followed by PMA
promotion generated sebaceous adenomas and melanocytic foci in GREKO and CO. Importantly, the number,
growth kinetics, and extent of both tumor types increased in GREKO mice, suggesting that in addition to
regulating tumorigenesis from epidermal lineages, GR in keratinocytes is important for cross-talk with other skin
cells. Altogether, our data reinforce the importance of GR in the pathogenesis of skin cancer.
Journal of Investigative Dermatology (2013) 133, 2771–2779; doi:10.1038/jid.2013.255; published online 11 July 2013
INTRODUCTION
Glucocorticoid (GC) derivatives are the most widely used
therapeutic agents for treating numerous cutaneous diseases
(Schmuth et al., 2007). In addition, GCs are routinely used in
cancer therapy as coadjuvants to reduce side effects of
chemotherapeutic agents, and their use as immunosuppressors
is standardized in clinical practice (De Bosscher and Haegeman,
2009; Barnes, 2011). It is thus crucial to understand the
mechanisms by which these compounds influence the
development and progression of skin tumors in order to
improve the design of combined therapies to combat cancer.
Both endogenous and synthetic GCs exert their actions
through the ubiquitous intracellular GC receptor (GR), a
member of the steroid nuclear receptor superfamily of
ligand-dependent transcription factors (De Bosscher and
Haegeman, 2009; Revollo and Cidlowski, 2009; Nicolaides
et al., 2010). GR is required for postnatal survival and has a
crucial role in skin pathophysiology, as demonstrated by the
generation and characterization of genetically modified mice
with both gain and loss of function of GR (Cole et al., 1995;
Tronche et al., 1999; Tuckermann et al., 1999; Pe´rez, 2011).
We previously reported that transgenic mice with
keratinocyte-specific GR overexpression were highly resistant
to developing skin papillomas, with fewer papillomas that
appeared with slower kinetics relative to control mice
(Budunova et al., 2003). However, whether mice lacking GR
in the epidermis would be more susceptible to tumorigenesis
was not known. We recently demonstrated that the selective
inactivation of GR in mouse epidermis (GR epidermal
knockout or (GREKO) mice) led to abnormal skin develop-
ment and exacerbated susceptibility to various epidermal
challenges in the adult age (Sevilla et al., 2013). In fact,
acute phorbol 12-myristate 13-acetate (PMA) treatment of
GREKO skin resulted in exaggerated epidermal keratinocyte
hyperproliferation and increased immune infiltrates.
With these antecedents, we examined the susceptibility of
GREKO mice to skin tumor formation and development using
two different protocols with distinct doses of initiating and
promoting agents (Abel et al., 2009). The use of either low or
high 12-dimethylbenz(a) anthracene (DMBA) dosage followed
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by distinct dosage of PMA produced either skin papillomas or
sebaceous tumors and dermal melanocytic foci (MFs),
respectively, in the mouse strain used in this study. GREKO
mice exhibited earlier kinetics of skin tumor growth, higher
tumor incidence and multiplicity, as well as increased tumor
size, as compared with control littermates (CO). Altogether,
our data reinforce the importance of GR in the pathogenesis of
skin cancer.
RESULTS AND DISCUSSION
Augmented sensitivity of GREKO mice to different protocols of
DMBA/TPA-induced skin carcinogenesis
We examined the susceptibility of GREKO mice to skin tumor
formation and development by using different dosage and
kinetics of the two-stage DMBA/PMA carcinogenesis protocol.
It is relevant to highlight that different mouse strains require
different concentrations of DMBA and PMA for effective tumor
formation in this protocol (Abel et al., 2009). In a first set of
experiments, the dorsal skin of age-matched GREKO and CO
mice was topically treated with a low dose of DMBA
(23nmol), followed by twice-weekly doses of PMA (10mg).
As expected, DMBA initiation caused mutation of H-ras in
codon 61 (A–T) in papillomas from both genotypes
(Supplementary Figure S1a online; Abel et al., 2009).
Papillomas developed in GREKO mice at 8 weeks after the
start of promotion and thereafter continued to increase in both
number and size (Figure 1a and b and Supplementary Figure
S2 online). In CO mice, papillomas were not detected until 10
weeks, and only 75% of animals developed tumors relative to
100% of GREKO mice (Supplementary Figure S2b online). We
observed an increase in both the average number of tumors
per mouse and the total number of tumors developed by
GREKO mice relative to their CO counterparts, with statistical
significance from 10 weeks onward (Figure 1a and
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Figure 1. Increased sensitivity of GREKO mice to DMBA/PMA-induced skin tumorigenesis and altered histopathology of GREKO tumors. (a) Papilloma
development evaluated in GREKO (n¼ 20) and CO littermates (n¼18) after a single dose of DMBA (23nmol) followed by 10mg PMA per mouse twice weekly for
19 weeks at the indicated times of promotion. (b) Mean tumor number (no.) per mouse (o2 and 42mm) determined at end point (18 male mice (8 CO and 10
GREKO) and 20 female mice (10 CO and 10 GREKO)). Average tumor numbers per mouse and statistical significance were determined; *Po0.05 and **Po0.01,
n¼ 56, Student’s t-test. (c–e, c0–e0) Representative hematoxylin and eosin (H&E) staining of 19-week papillomas collected from (c–e) CO and (c0–e0) GREKO
mice (n¼ 46 papillomas, 20 CO and 26 GREKO). Bars¼ 100mm. *Indicates keratin pearls, discontinuous lines indicate diffuse epidermal (Ep)–stromal (St) border,
and arrows indicate keratinocyte atypia (e´). (f, f 0) Immunostaining demonstrates delocalized expression of (f 0) laminin A and (g) keratin 5 (K5)–positive
keratinocytes invading the dermis (arrowheads) in GREKO tumors. (c–g) A total of 15 papillomas collected from 6 CO and 9 GREKO were analyzed. Bars (f, f 0)
¼100mm; (g) ¼ 50mm. CO, control littermate; DMBA, 12-dimethylbenz(a) anthracene; GREKO, glucocorticoid receptor epidermal knockout; PMA, phorbol 12-
myristate 13-acetate.
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Supplementary Figure S2b online). The mean number of
papillomaso2mm was 3-fold increased, whereas the average
number of tumors 24mm was 5-fold higher in GREKO relative
to CO mice (Figure 1b). We did not observe a statistical bias
toward the susceptibility to tumor formation by gender within
a given genotype (Supplementary Figure S2a online).
All CO tumors generated by this protocol were well-
differentiated papillomas, the epidermal–dermal border was
well defined, and tumor differentiation was histologically
evident by the presence of the so-called keratin pearls
(Figure 1c–e). GREKO skin tumors were also papillomas, but
they showed several features of poor differentiation including
a diffuse epidermal–dermal border and frequent signs of
keratinocyte atypia (Figure 1d0 and e0; discontinuous lines
and arrows). Moreover, the expression of laminin A was
delocalized in GREKO tumors instead of being confined to
the basement membrane of the epidermis, as in CO papillo-
mas (Figure 1f and f 0). These features were unique to GREKO
tumors, as adjacent skin showed similar epidermal hyperplasia
and basement membrane deposition of laminin as CO
(Supplementary Figure S3 online). In 40% of GREKO tumors
assessed, and none of CO, keratinocytes invaded the under-
lying dermis, as shown by K5 immunostaining (Supplementary
Figure S1g online, arrowheads).
In another set of experiments, a high DMBA dose
(390nmol) followed by three-times-weekly topical application
of PMA (6mg) for 31 weeks generated sebaceous adenomas, as
well as MFs in GREKO and CO littermates (Figure 2). The
generation of sebaceous tumors as well as the accumulation of
dermal melanocytes, which were visualized as nevi, have been
reported in other studies using similar high doses of DMBA in
different mouse strains (Rice and Anderson, 1986; Husain et al.,
1991; Indra et al., 2007). In both GREKO and CO mice, seba-
ceous tumors contained the characteristic A-to-T mutation in
codon 61 of the H-ras gene (Supplementary Figure S1a online).
GREKO mice showed early kinetics of sebaceous tumor
appearance relative to CO littermates (13 vs. 19 weeks), as
well as an elevated total tumor number (5- to 7-fold at late
stages of tumor promotion; Figure 2a); however, the histology
of GREKO sebaceous tumors was indistinguishable to that of
controls (Figure 2b and b0). The sebaceous glands of GREKO
mice are also targeted by the Krt5-driven recombinase, and
thus GR is inactivated in sebocytes (Supplementary Figure S1b
online). It has been reported that low levels of b-catenin and
activator protein-1 signaling can favor sebaceous instead of
epidermal tumor formation (Gerdes et al., 2006; Niemann
et al., 2007). We observed a decrease in the levels of b-
catenin and p-c-Jun in sebaceous tumors relative to the
epidermis of GREKO and CO mice; however, there were no
clear differences between genotypes (Supplementary Figure S4
online). Although we cannot rule out the contribution of other
signaling pathways to the development of sebaceous adeno-
mas in our experiment, it is likely that the doses and kinetics of
DMBA/PMA treatments together with the genetic background
are responsible for the generation of sebaceous rather than
epidermal tumors.
With regard to the MFs, their total number, kinetics of
growth, and extent were markedly increased in mice lacking
epidermal GR (Figure 2c, d, and d0). We detected a 3-fold
increase of these foci that appeared on average 3 weeks earlier
in GREKO relative to CO mice (Figure 2c). In addition, the MFs
in GREKO mice consistently invaded the deep dermis (Figure 2,
compare d and d´). As K5-Cre is not expressed in melanocytes
(Supplementary Figure S1b online), these data highlight a role
for keratinocytic GR in the regulation of other cell types that
populate the skin. Our data are consistent with previous
results describing that GCs can inhibit melanoma growth in
mice, and are also compatible with reports indicating that GC-
based therapy was protective against melanoma incidence in
a Mediterranean population (Landi et al., 2001).
Importantly, there were similarities in the response of GREKO
mice to chemical carcinogenesis protocols and that of mice
lacking skin expression of other nuclear hormone receptors
including retinoid X receptor a, peroxisome proliferator–
activated receptor g, and vitamin D receptor (Indra et al.,
2007). This is likely due to the production of soluble factors
such as En1, Fgf2, and Scf by keratinocytes, which contributes
to melanocyte activation and migration (Wang et al., 2011).
Analogous to these hormone receptors, the increased skin
tumor formation and progression of GREKO mice suggests a
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Figure 2. Increased incidence of sebaceous adenomas and melanocytic foci
(MFs) in glucocorticoid receptor epidermal knockout (GREKO) mice relative to
control (CO) mice after high-dose 12-dimethylbenz(a) anthracene (DMBA)
initiation and phorbol 12-myristate 13-acetate (PMA) promotion. (a) Skin
tumor and (c) MF development evaluated in GREKO (n¼10; 4 male mice and
6 female mice) and CO littermates (n¼8; 3 male mice and 5 female mice)
after a high dose of DMBA (390nmol), followed by 6mg PMA per mouse three
times a week for 31 weeks at the indicated times of promotion. Total numbers
of sebaceous tumors and MFs are represented. (b, b 0) Representative
hematoxylin and eosin (H&E) staining of 31-week sebaceous adenomas
(n¼ 18, 8 CO and 10 GREKO) and (d, d0) MFs (n¼ 14, 6 CO and 8 GREKO)
collected from each genotype. Note the greater extent of the MFs in GREKO
relative to CO mice. Bar¼ 100mm.
V Latorre et al.
Keratinocyte-Specific Lack of GR Increases Skin Tumorigenesis
www.jidonline.org 2773
role for GR as a tumor suppressor in both nonmelanoma and
melanoma skin cancers, as well as in the cross-talk between
keratinocytes and melanocytes.
Increased keratinocyte proliferation and inflammation in GREKO
skin papillomas
Consistent with the growth inhibitory role of GR in keratino-
cytes, the epidermal-specific loss of GR caused an increase in
basal keratinocyte proliferation of B30% in transgenic versus
CO tumors (Figure 3a, a0 and d). In addition, we observed
increased suprabasal (white arrows) keratinocyte proliferation
in GREKO tumors, whereas the majority of proliferation was
confined to the basal layer (black arrows) in CO. It is well
known that CycD1 is a key target for activated ras in the
mouse skin carcinogenesis protocol and that it is an indicator
of the proliferative response (Robles et al., 1998). We detected
augmented CycD1 expression in keratinocytes throughout
all epidermal layers (Figure 3b and b0), as well as strong
upregulation of Ccnd1 mRNA levels in GREKO tumors (data
not shown), which is consistent with the GR-mediated inhibi-
tion of this gene in mouse epidermis (Surjit et al., 2011).
GR exerts anti-inflammatory effects in skin and, accord-
ingly, the lack of GR in keratinocytes resulted in marked
immune infiltrates in the stroma (Figure 3e0, black arrows) as
well as within the epidermal layers of GREKO tumors
(Figure 3e0, white arrows). These histological changes corre-
lated with the increased expression of the proinflammatory
cytokine IL-6 in the GREKO tumor epithelia relative to CO
(Figure 3f and f0). As Il6 and other cytokines are transcriptional
targets of GR repression, we examined the relative mRNA
levels of Il6, Tnfa, and Il1b in the skin of GREKO and CO mice
adjacent to the tumors (Figure 3h). We detected statistically
significant upregulation of all cytokines (7-fold for Il6 and 2- to
3-fold for Tnfa and Il1b) in GREKO skin compared with CO
(Figure 3h), thus demonstrating that the lack of GR augments
cutaneous inflammation during carcinogenesis that may con-
tribute to the development and progression of skin tumors.
Altered keratinocyte differentiation and constitutively increased
AKT and STAT3 activities in GREKO skin papillomas
Well-differentiated benign papillomas express normal markers
of the epidermal basal (K5) and suprabasal (K10, loricrin)
layers, but not those of internal stratified epithelia such as K13
(Abel et al., 2009). Assessment of the expression of these
keratins is routinely used to classify papillomas into low,
intermediate, or high risk of malignant conversion. The
immunohistochemical analysis of CO skin tumors showed
the expression of K5 throughout all layers, as well as
suprabasal K10 and loricrin restricted to the most
differentiated outer layers (Figure 4a–c). We did not detect
any CO papilloma with K13 expression (Figure 4d). In
contrast, GREKO tumors showed a reduction in K10-positive
layers and focal loss of loricrin (Figure 4b0 and c0, arrowheads),
with 30% of the tumors staining positive for K13 (Figure 4d0).
Moreover, we detected reduced expression of the epithelial
marker E-cadherin, which mediates cell–cell adhesion, in
regions of GREKO but not in CO tumors (Figure 4e and e0).
Immunoblotting of protein extracts from papillomas for
E-cadherin failed to show a statistically significant difference
between genotypes, perhaps owing to the focal nature of the
decreased expression in GREKO tumors (not shown). Our data
show that augmented proliferation and inflammation, as well
as defective differentiation of epidermal keratinocytes lacking
GR, contributed to the accelerated onset and development of
skin tumors of GREKO mice. Overall, these features indicate
that the lack of epidermal GR triggers early stages of malignant
conversion in GREKO mouse skin tumors.
Previous reports have demonstrated that several signaling
pathways including AKT, extracellular signal–regulated kinase
(ERK), and signal transducer and activator of transcription 3
(STAT3) have a critical role throughout the process of
epithelial carcinogenesis in mouse skin (Segrelles et al.,
2002; Kataokay et al., 2008). We have also shown that AKT
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Figure 3. Increased keratinocyte proliferation and inflammation in
glucocorticoid receptor epidermal knockout (GREKO) mice skin papillomas.
(a, a0) GREKO papillomas showed increased BrdU-positive keratinocytes and
(b, b0) augmented Cyclin D1 (CycD1) expression; (c) negative control staining
(slides incubated with secondary antibody (2nd Ab) alone). Bars¼100mm.
Basal (black arrow) and suprabasal (white arrows) keratinocytes are indicated.
(d) Percentage and statistical significance (*Po0.05, n¼ 13, Student’s t-test) of
BrdU-positive basal keratinocytes. (e, e0) Hematoxylin and eosin (H&E) staining
of GREKO papillomas showing marked immune infiltrates within the epidermis
(white arrows) and the tumor stroma (black arrows) of GREKO mice.
(f, f 0) Immunohistochemistry (IH) for IL-6. (g) Negative control. Bars (e, e0)¼
100mm; (f, f 0, g)¼ 50mm. (a–g) A total of 13 papillomas collected from 5
control (CO) and 8 GREKO mice were analyzed. (h) Relative mRNA levels of
Il6, Tnfa, and Il1b quantified by quantitative reverse-transcriptase–PCR (Q-RT-
PCR) in GREKO and CO skin adjacent to tumors. Mean values± SD are shown
(*Po0.05, n¼ 7 skin samples collected from 3 CO and 4 GREKO, Student’s
t-test).
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and ERK activities were constitutively increased in the
epidermis of mice with either total or keratinocyte-specific
inactivation of GR (Bayo et al., 2008; Sevilla et al., 2013).
Moreover, growth kinetics and malignancy of skin tumors
induced by the injection of AKT-transfected mouse
keratinocytes was greatly reduced by GR coexpression
owing to a nongenomic interaction of GR and p85a/
phosphatidylinositol-3-kinase (Leis et al., 2004). Accordingly,
we examined whether the increased sensitivity of GREKO mice
to develop epidermal tumors correlated with the increased
activity of these signaling pathways. Phosphorylated (p)-ERK is
normally restricted to the granular layer of the epidermis
(Figure 4f, white arrows); however, increased levels of p-ERK
were detected in all epidermal layers in GREKO tumors
(Figure 4f 0, white and black arrows). p-AKT was detected in
tumors from both genotypes, although the levels and the
number of positive cells were increased in GREKO relative to
CO mice (Figure 4g and g0). STAT3 was localized in some
nuclei of CO epidermal tumors (Figure 4h), whereas virtually
all nuclei of GREKO tumors were STAT3 positive (Figure 4h0),
consistent with the critical role of this transcription factor in
multistage epithelial carcinogenesis (Kataokay et al., 2008).
Quantification of immunoblotting experiments showed that
the ratios of both p-AKT/AKT and p-STAT3/STAT3, but not
p-ERK/ERK, were increased with statistical significance in
GREKO relative to CO papillomas (Figure 4i and j). The
inability to observe changes in p-ERK levels may be due to
dilution effects, as stromal cells are also present in the protein
extracts. These results suggest that the lack of epidermal GR
not only accelerates the growth of epidermal tumors but also
increases their malignancy, likely owing, at least in part, to the
increased activation of the AKT and STAT3 pathways.
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Figure 4. Altered keratinocyte differentiation and constitutively increased AKT and signal transducer and activator of transcription 3 (STAT3) activities in
glucocorticoid receptor epidermal knockout (GREKO) mice skin papillomas. (a–c, a0–c0) Immunostaining for keratin 5 (K5), K10, and loricrin (LOR) shows
abnormal differentiation of GREKO skin tumors relative to control (CO) mice. Arrowheads indicate local negative staining for K10 and loricrin. (d, e, d0, e0) Positive
staining for K13 and focal reduced E-cadherin (E-CAD) immunostaining of GREKO tumors indicates early malignization. (f–h, f 0–h0) Immunostaining for
phosphorylated extracellular signal–regulated kinase (p-ERK), phosphorylated (p)-AKT, and STAT3 shows constitutively increased activities/nuclear localization in
GREKO relative to CO epithelial tumors. White and black arrows denote suprabasal and basal staining, respectively. Bars¼ 100mm. (a–h) A total of 11 papillomas
collected from 4 CO and 7 GREKO were analyzed. (i, j) Representative immunoblot and quantification of three experiments show relative expression and ratios of
phosphorylated and total ERK, AKT, and STAT3 in GREKO and CO papillomas. Actin, loading control. Mean values± SD are shown (*Po0.05, n¼ 12 papillomas
collected from 5 CO and 7 GREKO, Student’s t-test).
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GR deficiency alters cytoskeletal architecture and triggers a
partial epithelial–mesenchymal transition (EMT) in cultured
keratinocytes
Given that GREKO mouse skin tumors featured signs of
malignant conversion (Figures 1 and 4), we further analyzed
the morphology and cell–cell interactions of GREKO versus
CO cultured keratinocyte cell lines (Sevilla et al., 2013).
At confluency, GREKO keratinocytes featured marked
morphological alterations, showing spindle-like phenotype
suggestive of a partial EMT (Figure 5a and a0; Moreno-Bueno
et al., 2009). This was confirmed by immunofluorescence
staining for E-cadherin and smooth muscle actin (SMA), as
epithelial and mesenchymal expression markers, respectively.
Whereas confluent CO keratinocytes exposed to 1.2mM
calcium showed E-cadherin-mediated cell–cell contacts,
GREKO keratinocytes showed decreased cell–cell contacts with
almost undetectable E-cadherin expression levels (Figure 5b
and b0). Consistent with the absence of E-cadherin, GREKO
keratinocytes did not form mature intercellular junctions
shown by the reduced accumulation of b-catenin and desmo-
plakin at sites of cell–cell contact (Figure 5c, c0, d, and d0).
Importantly, the expression of SMA was greatly increased in
GREKO keratinocytes, although these cells still retained K5
expression (Figure 5e and e0). These results were further
confirmed by immunoblotting (Figure 5g and h). Downregula-
tion of E-cadherin is mediated by members of the Snail family
of proteins through binding to an E-box located in its promoter
(Moreno-Bueno et al., 2009). Indeed, we detected a
statistically significant increase in Snail but not Slug/Snai2
levels in GREKO relative to CO keratinocytes (Figure 5g and h).
These data are consistent with the observation that Dex-
activated GR abolished Snail binding to the E-cadherin
promoter in lung epithelial cells, thus contributing to EMT
suppression (Zhang et al., 2010). The observed changes in
GREKO cultured keratinocytes were independent of media
composition (Supplementary Figure S5 online).
We evaluated the actin cytoskeleton by phalloidin staining
and observed a reduction in cortical actin and an increase
in stress fibers in GREKO versus CO cells (Figure 5f and f0),
another hallmark of EMT (Moreno-Bueno et al., 2009). As
cytoskeleton reorganization could be linked to altered cell
motility, we evaluated the migration of GREKO versus CO
keratinocytes in a scratch wound assay but did not detect
statistically significant changes in wound closure (not shown).
This might be related to the lack of Slug upregulation in GREKO
keratinocytes, which is essential for re-epithelialization of
healing wounds and cannot be substituted by Snail (Sou
et al., 2010).
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Figure 5. Epidermal glucocorticoid receptor (GR) deficiency triggers a partial epithelial–mesenchymal transition in cultured keratinocytes. (a–f, a0–f 0)
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with 1.2mM calcium before fixation. DAPI, 4’,6-diamidino-2-phenylindole. In a and a´, keratinocytes were grown for an additional 48hours after confluency.
Bars¼ 50mm. (g) Immunoblotting determined the relative expression of GR, E-cadherin, SMA, Snail, Slug, and K5 in GREKO and CO cultured keratinocytes.
Tubulin, loading control. (h) Quantification of four independent experiments shows relative expression of the indicated proteins in GREKO compared with CO
keratinocytes. Protein levels were arbitrarily set to 1 in CO cells. Mean values±SD are shown (*Po0.05 and **Po0.01, n¼4, Student’s t-test).
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Our in vitro results were consistent with the in vivo findings
showing that the lack of epidermal GR increases the malig-
nancy of epidermal tumors (Figures 1, 4, and 5). However,
immunoblotting of protein extracts from tumors of both
genotypes did not show statistically significant changes in
E-cadherin or SMA (not shown), likely owing to the fact that
in vivo EMT is restricted to a subset of tumor cells. There are
contradictory reports regarding the role of GR in EMT, and
cell-type specificity seems to be key for the final outcome of
GC treatments. Recent studies have shown negative regulation
of GCs in the process of EMT, which is vital for tumor invasion
and metastasis (Godoy et al., 2010; Zhang et al., 2010;
Ferrand et al., 2012).
Given the immunosuppressive effects of GCs, there has
been concern that their chronic use was associated with an
increased risk of several cancers, including nonmelanoma and
melanoma skin cancer. The epidemiological data are con-
troversial, claiming either no association between the use of
GCs and cancer risk or a modestly increased risk of basal or
squamous cell carcinoma (Karagas et al., 2001; Sorensen
et al., 2004; Askling et al., 2005; Baecklund et al., 2006;
Jensen et al., 2009). However, it is feasible that the reported
increase of cancer risk is due to the inflammatory condition of
the chronic diseases being treated and the use of other
immunosuppressive agents rather than to the contribution of
GCs per se. The use of a mouse model with epidermal GR
ablation demonstrates that GR negatively regulates the
formation and early malignization of DMBA/PMA-induced
epidermal tumors, as well as the development of sebaceous
tumors and MFs. Our findings highlight the complexity of GR
action in tumorigenesis, as well as the relevance of epidermal
GR for cross-talk with other skin cells.
MATERIALS AND METHODS
Animal experimentation and skin carcinogenesis protocols
GREKO mice and genotyping of the transgenic colonies has been
previously reported (Sevilla et al., 2013). Briefly, K5-creþ / //GRloxP/loxP
male mice were crossed with 0-cre//GRloxP/loxP female mice, and the
resulting adult progeny (K5-creþ / //GRloxP/loxP or GREKO and 0-cre//
GRloxP/loxP or CO mice) were used for the indicated experiments
(n¼ 56). The genetic background of the transgenic line was C57BL/
6J//DBA/2J.
Two protocols with different doses of DMBA/PMA were used,
where GREKO and CO mouse littermates were DMBA initiated at the
age of 8 weeks. In the first protocol, a single dose of DMBA was
applied (23nmol), followed by repeated topical treatments with PMA
(10mg per mouse twice weekly for 19 weeks; n¼ 38: 18 male mice
(8 CO and 10 GREKO) and 20 female mice (10 CO and 10 GREKO)). In
the second protocol, DMBA (390nmol) was applied at a single dose,
followed by repeated topical PMA treatments (6mg per mouse three
times weekly for 31 weeks; n¼ 18: 7 male mice (3 CO and 4 GREKO)
and 11 female mice (5 CO and 6 GREKO)). The appearance of tumors
and abnormally pigmented skin (located on dorsal and lateral skin)
was recorded weekly. Tumors and adjacent skin were collected at
experimental end points, and either fixed in 4% paraformaldehyde or
70% ethanol or snap-frozen in liquid nitrogen for future isolation of
RNA and protein. A variable number of tumors and MFs was
collected from each genotype to perform histopathological analysis,
as well as RNA and protein isolation. For histopathological analysis,
46 papillomas (20 papillomas collected from 18 CO and 26
papillomas collected from 20 GREKO); 18 sebaceous adenomas
(8 collected from 8 CO and 10 collected from 10 GREKO); and 14
MFs (6 collected from 6 CO and 8 collected from 8 GREKO) were
evaluated. At least 10 papillomas and 10 sebaceous adenomas were
used for immunostaining.
Differences in the average number of papillomas per mouse during
tumor promotion were assessed using the Student’s t-test, and
statistical significance among genotypes was indicated (Po0.05).
The major axis of tumors was measured at the experimental end
point, and the mean number of papillomas per mouse greater or less
than 2mm was calculated; statistical significance of differences
between genotypes was determined using the Student’s t-test
(Po0.05).
Mice were housed in standard temperature and humidity condi-
tions, and experimentation was conducted with accepted standards of
humane care in our animal facility (IBV-CSIC). Experiments were
performed in accordance with the current Spanish and European
normative that governs research with animals (Real Decreto 1201/
2005, BOE 252, 10 October, 2005 and Convenio Europeo 1-2-3 del
18/3/1986).
RNA isolation and quantitative reverse-transcriptase–PCR
Total RNA was isolated from skin adjacent to tumors of GREKO and
CO mice (at least five animals of each genotype) using Trizol
(Invitrogen Life Technologies, Carlsbad, CA). Complementary DNA
was generated from 1mg of total RNA using RevertAid H Minus
Reverse Transcriptase and oligo-dTs (Thermo Fisher Scientific,
Waltham, MA), followed by quantitative PCR using specific
oligonucleotides for each of the genes tested and FastStart Universal
SYBR Green Master Rox (Roche Applied Science, Branford, CT) in
an Applied Biosystems 7500 Fast real-time PCR system (Life Technol-
ogies, Carlsbad, CA). Oligonucleotide sequences were as follows:
Il6F, 50-GATGCTACCAAACTGGATATAATC-30; Il6R, 50-GGTCCTTA
GCCACTCCTTCTGTG-30; TnfaF, 50-CCCTCACACTCAGATCATCT
TCT-30; TnfaR, 50-GCTACGACGTGGGCTACAG-30; Il1bF, 50-GCAAC
TGTTCCTGAACTCAACT-30; and Il1bR, 50-ATCTTTTGGGGTCCGT
CAACT-30. At least three biological replicates were used for each
experimental group, and technical triplicates were assessed to
calculate the mean value ± SD. Statistical significance was calcu-
lated using the Student’s t-test, Po0.05.
Antibodies
The following rabbit polyclonal antibodies specific for Actin (A2668,
Sigma-Aldrich, St Louis, MO), p-AKT (ser-473, 9271, Cell Signaling
Technology, Beverly, MA), b-catenin (sc-7199, Santa Cruz Biotech-
nology, Santa Cruz, CA), Desmoplakin (Ab14418, Abcam, Cam-
bridge, MA), ERK (sc154, Santa Cruz Biotechnology), p-ERK (Thr202/
Tyr204, 4376, Cell Signaling Technology), IL-6 (407670, Calbiochem,
San Diego, CA), GR (sc-1004, Santa Cruz Biotechnology), K5 (PRB-
160P, Covance, BAbCo, Berkeley, CA), K10 (PRB-159P, Covance),
K13 (Ab16112, Abcam), Loricrin (PRB-145P, Covance), MR
(Ab64457, Abcam), Slug (9585, Cell Signaling Technology), and
STAT3 (9132, Cell Signaling) were used.
The rabbit mAb for p-STAT3 was from Cell Signaling Technology
(9145) and goat anti-AKT was from Santa Cruz Biotechnology
(sc1619).
V Latorre et al.
Keratinocyte-Specific Lack of GR Increases Skin Tumorigenesis
www.jidonline.org 2777
The following mouse mAbs specific for CyclinD1 (sc-450, Santa
Cruz Biotechnology), E-cadherin (610181, BD Biosciences, San Jose,
CA), p-c-Jun (sc822, Santa Cruz Biotechnology), SMA (Ab18147,
Abcam), Snail (3895, Cell Signaling Technology), and Tubulin (clone
DM1A, Sigma-Aldrich) were used.
Histological and immunohistochemical analysis
Fixed tumor and skin samples were embedded in paraffin. Consecu-
tive 4-mm-thick sections were stained with hematoxylin and eosin for
histopathological analysis. Before immunostaining, paraffin sections
were dewaxed and microwaved in 10mM citrate solution, and then
blocked with 5% fetal bovine serum, and incubated with primary
antibody overnight. Slides were washed three times with phosphate-
buffered saline, incubated with biotin-conjugated secondary antibo-
dies for 1 hour (Jackson ImmunoResearch, West Grove, PA), and
visualized with the Avidin–Biotin Complex (ABC) kit from DAKO
(Vectastain Elite, Vector Laboratories, Burlingame, CA) using dia-
mino-benzidine as chromogenic substrate for peroxidase. Slides were
mounted and analyzed by light microscopy (Leica DM RXA2, Leica
Microsystems, Wetzlar, Germany).
In vivo epidermal BrdU labeling
Epithelial cell proliferation was measured by intraperitoneal injection
of BrdU (130mg per g of body weight; Roche Applied Science) 1 hour
before killing. BrdU incorporation was detected by immunohisto-
chemistry of paraffin-embedded sections using a mouse anti-BrdU
monoclonal antibody (Roche Applied Science). The number of BrdU-
positive and total cells was determined per 200mm of interfollicular
epithelium in each section. Experiments were performed in at least six
individuals of each genotype, and statistical significance was assessed
using the Student’s t-test (Po0.05).
Immunoblotting
Whole-cell extracts (30mg) were prepared as previously described
(Sevilla et al., 2013), boiled in Laemmli buffer, separated on 8% SDS-
PAGE; and then transferred to nitrocellulose filters (Hybond ECL, GE
Healthcare, Barcelona, Spain). The membranes were stained with
Ponceau S (Sigma-Aldrich) to verify equal protein loading and
transfer. Filters were blocked for 1 hour with 5% nonfat dry milk in
phosphate-buffered saline/0.1% Tween-20 and incubated with the
indicated antibodies overnight at 41C. After washing with phosphate-
buffered saline/0.1% Tween-20, membranes were incubated with a
peroxidase-conjugated secondary antibody (GE Healthcare), washed,
and analyzed using the enhanced chemiluminiscence method (GE
Healthcare), with the ImageQuant 4000 Biomolecular Imager (GE
Healthcare). Representative panels for each immunoblot are shown
along with quantification of at least three independent experiments.
Cell culture and immunofluorescence
GREKO and CO keratinocyte cell lines were generated from 8-week-
old mouse dorsal skin, as previously described (Sevilla et al., 2013),
and cultured in DMEM/Ham’s F12 (3:1) medium supplemented with
1.8 10 4mol l 1 adenine, 0.35mM calcium, 10% chelex-treated
fetal calf serum, 5mgml 1 insulin, 10 10M cholera toxin, and
10ngml 1 EGF.
To visualize cytoskeletal rearrangements and intercellular junc-
tions, cells grown on coverslips were incubated with 1.2mM calcium
for 4 hours before fixation with 4% paraformaldehyde. After washing
with phosphate-buffered saline, permeabilization with 0.2% Triton
X-100, and blocking in 5% donkey serum and 0.5% BSA, cells were
incubated with primary antibody overnight at 4 1C. After washing,
cells were incubated with Alexa Fluor–conjugated (488 or 555)
secondary antibodies (Life Technologies) and, where indicated, with
TRITC-phalloidin (Sigma-Aldrich) or 4’,6-diamidino-2-phenylindole
(Life Technologies). Samples were mounted using Mowiol (Calbio-
chem) and analyzed using a Leica DM 1000 microscope.
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